Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Kura Oncology (KURA) Income towards Parent Company: 2024-2025

Historic Income towards Parent Company for Kura Oncology (KURA) over the last 2 years, with Sep 2025 value amounting to -$74.1 million.

  • Kura Oncology's Income towards Parent Company fell 36.23% to -$74.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$214.9 million, marking a year-over-year change of. This contributed to the annual value of -$174.0 million for FY2024, which is 13.99% down from last year.
  • Per Kura Oncology's latest filing, its Income towards Parent Company stood at -$74.1 million for Q3 2025, which was down 12.09% from -$66.1 million recorded in Q2 2025.
  • Over the past 5 years, Kura Oncology's Income towards Parent Company peaked at -$17.2 million during Q4 2024, and registered a low of -$74.1 million during Q3 2025.
  • In the last 2 years, Kura Oncology's Income towards Parent Company had a median value of -$54.4 million in 2024 and averaged -$52.8 million.
  • Data for Kura Oncology's Income towards Parent Company shows a maximum YoY plummeted of 36.23% (in 2025) over the last 5 years.
  • Kura Oncology's Income towards Parent Company (Quarterly) stood at -$17.2 million in 2024, then tumbled by 36.23% to -$74.1 million in 2025.
  • Its last three reported values are -$74.1 million in Q3 2025, -$66.1 million for Q2 2025, and -$57.4 million during Q1 2025.